US4333940A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Ring-fluorinated 4-(monosubstituted-amino) phenyl compounds in inhibiting atherosclerotic lesion development
Assignee: Wyeth Holdings LLC
•
Filing: 1980-08-11
•
Granted: 1982-06-08
•
Expires: 2000-08-11
Abstract
Abstract The present invention relates to the use of certain ring-fluorinated 4-(monosubstituted-amino) phenyl compounds as hypolipidemic and antiatherosclerotic agents together with their pharmacologically acceptable acid-addition and cationic salts.
Inventors
- 👤 Robert G. Shepherd
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-10 00:44
CPC Classifications
C; C07; C07D; C07D213/00; C07D213/02; C07D213/04; C07D213/24; C07D213/28; C07D213/30; C07C; C07C17/00; C07C17/093; C07C323/00; C07C323/23; C07C323/24; C07C323/25; C07C327/00; C07C327/20; C07C327/22; C07C45/00; C07C45/45; C07D207/00; C07D207/02; C07D207/30; C07D207/34; C07D207/42; C07D211/00; C07D211/04; C07D211/06; C07D211/36; C07D211/40; C07D211/44; C07D211/46; C07D213/60; C07D213/62; C07D213/63; C07D213/65; C07D213/78; C07D213/79; C07D213/80; C07D233/00; C07D233/54; C07D233/64; C07D239/00; C07D239/02; C07D239/24; C07D239/28; C07D239/32; C07D239/42; C07D263/00; C07D263/02; C07D263/08; C07D263/10; C07D265/00; C07D265/04; C07D265/06; C07D277/00; C07D277/02; C07D277/04; C07D277/06; C07D303/00; C07D303/02; C07D303/12; C07D303/16; C07D307/00; C07D307/02; C07D307/34; C07D307/38; C07D307/54; C07D307/56; C07D307/66; C07D307/68; C07D307/70; C07D307/71; C07D309/00; C07D309/02; C07D309/08; C07D309/10; C07D309/12; C07D317/00; C07D317/08; C07D317/10; C07D317/14; C07D317/28; C07D333/00; C07D333/02; C07D333/04; C07D333/06; C07D333/14; C07D333/16; C07D333/20; C07D333/22; C07D333/24; C07D333/26; C07D333/30; C07D333/36; C07D333/38; C07D333/42; C07D333/44
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
193 words
The method of inhibiting atherosclerotic lesion development in a mammal comprising the administration of an effective lesion-development inhibiting amount of a compound of the formula: ##STR3## wherein R 1 is an unbranched or branched alkyl group, optionally mono- or polyunsaturated and optionally containing saturated or unsaturated cycloalkyl and/or substituted or unsubstituted aryl or heteroaryl groups, of the formula C n H 2n- (2p-1), n is an integer from 7 to 19, inclusive, and p is an integer up to 6; m is an integer from 1 to 4, inclusive; Z is selected from the group consisting of hydrogen, loweralkyl, hydroxy, loweralkoxy, loweralkoxyalkoxy, diloweralkylaminoalkoxy, (mono- or polyhydroxy)loweralkoxy, allyloxy, 2,3-epoxypropoxy, substituted or unsubstituted benzyloxy, substituted or unsubstituted phenoxy and 3-pyridyloxy, pyridylmethoxy, (mono- or polycarboxy)loweralkoxy, (mono- or polycarboxy)hydroxyloweralkoxy, tetrahydropyranyloxy, (mono- or polyhydroxy)alkylamino, allylamino, propargylamino, 2-sulfoethylamino, (mono- or polycarboxy)loweralkylamino, (mono- or polycarboalkoxy)loweralkylamino, loweralkanoylamino, (substituted or unsubstituted aroyl)amino, loweralkanesulfonylamino, (substituted or unsubstituted arene)-sulfonylamino, loweralkanoylhydrazino, hydroxylamino, polymethyleneimino, 4-carboethoxy or 4-carboxythiazolidino, loweralkyl bearing one or more carboxy, carboalkoxy, carbamoyl, acyl, sulfinyl, or sulfonyl groups; and wherein ##STR4## may be replaced by carboxyloweralkyl, carboxyloweralkenyl, carboxyloweralkynyl, carboalkoxyloweralkyl, carboalkoxyloweralkenyl, carboalkoxyloweralkynyl, and the pharmacologically acceptable acid addition and cationic salts thereof to said mammal.
Claim 2
Independent Claim
193 words
The method of inhibiting atherosclerotic lesion development in a mammal comprising the administration of an effective lesion-development inhibiting amount of a compound of the formula: ##STR3## wherein R 1 is an unbranched or branched alkyl group, optionally mono- or polyunsaturated and optionally containing saturated or unsaturated cycloalkyl and/or substituted or unsubstituted aryl or heteroaryl groups, of the formula C n H 2n- (2p-1), n is an integer from 7 to 19, inclusive, and p is an integer up to 6; m is an integer from 1 to 4, inclusive; Z is selected from the group consisting of hydrogen, loweralkyl, hydroxy, loweralkoxy, loweralkoxyalkoxy, diloweralkylaminoalkoxy, (mono- or polyhydroxy)loweralkoxy, allyloxy, 2,3-epoxypropoxy, substituted or unsubstituted benzyloxy, substituted or unsubstituted phenoxy and 3-pyridyloxy, pyridylmethoxy, (mono- or polycarboxy)loweralkoxy, (mono- or polycarboxy)hydroxyloweralkoxy, tetrahydropyranyloxy, (mono- or polyhydroxy)alkylamino, allylamino, propargylamino, 2-sulfoethylamino, (mono- or polycarboxy)loweralkylamino, (mono- or polycarboalkoxy)loweralkylamino, loweralkanoylamino, (substituted or unsubstituted aroyl)amino, loweralkanesulfonylamino, (substituted or unsubstituted arene)-sulfonylamino, loweralkanoylhydrazino, hydroxylamino, polymethyleneimino, 4-carboethoxy or 4-carboxythiazolidino, loweralkyl bearing one or more carboxy, carboalkoxy, carbamoyl, acyl, sulfinyl, or sulfonyl groups; and wherein ##STR4## may be replaced by carboxyloweralkyl, carboxyloweralkenyl, carboxyloweralkynyl, carboalkoxyloweralkyl, carboalkoxyloweralkenyl, carboalkoxyloweralkynyl, and the pharmacologically acceptable acid addition and cationic salts thereof to said mammal.
Claim 3
Independent Claim
76 words
The method of inhibiting atherosclerotic lesion development in a mammal comprising the administration of an effective lesion-development inhibiting amount of a compound of the formula: ##STR5## wherein C 16 H 33 represents an unbranched or branched hexadecyl group and Z is selected from the group consisting of hydroxy, hydrogen, 2,3-dihydroxypropyloxy, carboxymethoxy, loweralkanesulfonylamino, substituted or unsubstituted arenesulfonylamino, loweralkanoylamino, (substituted or unsubstituted aroyl)amino, carboxyalkylamino, or 1-sulfoethylamino, and the pharmacologically acceptable acid-addition and cationic salts thereof to said mammal.
Claim 4
Independent Claim
76 words
The method of inhibiting atherosclerotic lesion development in a mammal comprising the administration of an effective lesion-development inhibiting amount of a compound of the formula: ##STR5## wherein C 16 H 33 represents an unbranched or branched hexadecyl group and Z is selected from the group consisting of hydroxy, hydrogen, 2,3-dihydroxypropyloxy, carboxymethoxy, loweralkanesulfonylamino, substituted or unsubstituted arenesulfonylamino, loweralkanoylamino, (substituted or unsubstituted aroyl)amino, carboxyalkylamino, or 1-sulfoethylamino, and the pharmacologically acceptable acid-addition and cationic salts thereof to said mammal.
Claim 5
Dependent Claim
32 words
The method of claim 1, wherein said compound is administered to provide a daily dosage of from about one mg. to about 250 mg. per kilogram of body weight of said mammal.
Claim 6
Dependent Claim
32 words
The method of claim 2, wherein said compound is administered to provide a daily dosage of from about one mg. to about 250 mg. per kilogram of body weight of said mammal.
Claim 7
Dependent Claim
40 words
An antiatherosclerotic composition in dosage-unit form useful for preventing or diminishing atherosclerotic lesion formation in mammals comprising from about one mg. to about 250 mg. per kilogram of body weight per daily dosage unit of a compound of claim 1.
Claim 8
Dependent Claim
40 words
An antiatherosclerotic composition in dosage-unit form useful for preventing or diminishing atherosclerotic lesion formation in mammals comprising from about one mg. to about 250 mg. per kilogram of body weight per daily dosage unit of a compound of claim 2.
Claim 9
Dependent Claim
27 words
The method of inducing regression of atherosclerotic lesion development in a mammal comprising administering to said mammal an effective lesion-regressive amount of a compound of claim 1.
Claim 10
Dependent Claim
27 words
The method of inducing regression of athersclerotic lesion development in a mammal comprising administering to said mammal an effective lesion-regressive amount of a compound of claim 2.
Claim 11
Dependent Claim
32 words
The method of claim 7, wherein said compound is administered to provide a daily dosage of from about one mg. to about 250 mg. per kilogram of body weight of said mammal.
Claim 12
Dependent Claim
32 words
The method of claim 8, wherein said compound is administered to provide a daily dosage of from about one mg. to about 250 mg. per kilogram of body weight of said mammal.
Claim 13
Dependent Claim
30 words
The method of treating hyperlipidemia and hyperlipoproteinemia and/or altering the lipoprotein pattern in a mammal comprising administration to said mammal an effective lipid-altering amount of a compound of claim 1.
Claim 14
Dependent Claim
30 words
The method of treating hyperlipidemia and hyperlipoproteinemia and/or altering the lipoprotein pattern in a mammal comprising administration to said mammal an effective lipid-altering amount of a compound of claim 2.
References Cited (Backward Citations)
US3340297A
Cited
US3245913A
Cited
US3787478A
Cited
US3868416A
Cited
US4036977A
Cited
US4133890A
Cited
US4143151A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-06-07 | 1985-12-07 | 1986-06-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-06-07 | 1989-12-07 | 1990-06-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-06-07 | 1993-12-07 | 1994-06-08 | $7700.00 | Window Closed / Lapsed |